Healthcare services company Sotera Health (NASDAQ: SHC) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.2% year on year to $321.4 million. The company expects the full year’s revenue to be around $1.25 billion, close to analysts’ estimates. Its non-GAAP profit of $0.26 per share was 8.7% above analysts’ consensus estimates.

Is now the time to buy SHC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Sotera Health’s second quarter was marked by broad-based growth across its business units, which drove a positive market reaction. Management credited robust demand in both core sterilization (Sterigenics) and isotope supply (Nordion), coupled with improved customer engagement at Nelson Labs, for the outperformance. CEO Alton Shader highlighted that "Sterigenics built on strong momentum from Q1, delivering 7% constant currency revenue growth," while Nordion benefited from favorable Cobalt-60 shipment timing. The company also benefited from higher pricing and operational efficiencies, with Shader emphasizing the importance of customer relationships and technical expertise in differentiating Sotera Health’s offerings.

Looking ahead, management’s updated guidance is anchored by expectations of continued resilience across its portfolio and additional growth drivers in the second half of the year. Shader pointed to the ramp-up of a new X-ray sterilization facility and the onboarding of a large customer shifting from in-house to outsourced sterilization as key contributors. He stated, "We see a meaningful uptick in growth in Sterigenics in the second half of the year," and underscored ongoing investments in capacity and operational improvements. CFO Jonathan Lyons added that the company’s capital allocation will prioritize growth initiatives and strategic projects to support future expansion.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to strong execution across Sterigenics, Nordion, and Nelson Labs, alongside improved pricing, capacity investments, and a smooth CEO transition.

• Leadership transition completed: Alton Shader became CEO, succeeding Michael Petras, with Petras remaining as Executive Chairman. Shader’s arrival was marked by an emphasis on customer focus, talent development, and building on the company’s strong foundation.
• Sterigenics demand stable: The core sterilization segment delivered robust growth, supported by higher pricing and volume gains in both medical and bioprocessing customers. Management noted continued stability in demand and no significant change in the competitive landscape.
• Nordion shipment timing boost: Nordion, which supplies isotopes for sterilization, saw revenue growth benefit from timing of Cobalt-60 shipments, with some expected second-half deliveries pulled forward into the second quarter. This contributed to stronger-than-expected segment results.
• Nelson Labs customer wins: The laboratory testing division outperformed due to new customer projects and ongoing demand for technical expertise, with Shader noting both one-off and recurring business wins that supported revenue and margin improvement.
• Capacity and technology investments: Management highlighted ongoing investments in expanding sterilization capacity, including X-ray and EO (ethylene oxide) facility upgrades, and clean room expansions at Nelson Labs. These projects are expected to drive future growth and operational leverage.

Drivers of Future Performance

Sotera Health’s guidance is driven by operational investments, cross-segment collaboration, and expected volume increases, but also reflects risks from inflation and litigation.

• Sterigenics growth drivers: Management expects Sterigenics to benefit from new X-ray capacity coming online, favorable facility shutdown schedules, and the addition of a large customer outsourcing sterilization. This is anticipated to support mid- to high-single digit growth and sustained margin expansion.
• Capital allocation and cost discipline: The company is prioritizing capital spending on capacity expansions and facility enhancements, particularly in sterilization and laboratory services. Management also expects a step-down in capital expenditures after 2026 and is evaluating future uses of free cash flow, including potential M&A.
• Margin and pricing environment: While cost inflation remains typical in labor and materials, management sees no extraordinary pressures. The company maintains its long-term pricing strategy of 3% to 4% annual increases, including passing on costs for enhanced safety and environmental requirements in EO facilities. Litigation risks, though not currently material, remain an ongoing consideration for future profit projections.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team will be closely monitoring (1) the ramp-up of new X-ray sterilization capacity and associated revenue contribution, (2) the onboarding progress of the large customer outsourcing sterilization services, and (3) continued execution on cross-segment commercial strategies, especially between Sterigenics and Nelson Labs. Developments in ongoing litigation and updates on capital deployment priorities will also be important to track.

Sotera Health Company currently trades at $18.89, up from $17.98 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.